title: Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer.
authors.affiliation: Leeds Institute of Molecular Medicine, St. James University Hospital, Leeds, United Kingdom. c.j.twelves@leeds.ac.uk
authors.forename: Chris
authors.initials: C
authors.lastname: Twelves
authors.forename: Javier
authors.initials: J
authors.lastname: Cortes
authors.forename: Linda T
authors.initials: LT
authors.lastname: Vahdat
authors.forename: Jantien
authors.initials: J
authors.lastname: Wanders
authors.forename: Corina
authors.initials: C
authors.lastname: Akerele
authors.forename: Peter A
authors.initials: PA
authors.lastname: Kaufman
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D005663:Furans / Q000627:therapeutic use*; D006801:Humans; D007659:Ketones / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology; D000095662:Polyether Polyketides
chemical_list: D000970:Antineoplastic Agents; D005663:Furans; D007659:Ketones; C490954:eribulin; D000095662:Polyether Polyketides